Skip Navigation



Journal of the National Cancer Institute Advance Access published online on October 28, 2008
JNCI Journal of the National Cancer Institute, doi:10.1093/jnci/djn351
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/21/1500    most recent
djn351v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Hollingshead, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hollingshead, M. G.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press 2008.

COMMENTARY

Antitumor Efficacy Testing in Rodents

Melinda G. Hollingshead

Affiliation of author: Biological Testing Branch, Developmental Therapeutics Program, National Cancer Institute, Frederick, MD

Correspondence to: Melinda G. Hollingshead, DVM, PhD, Biological Testing Branch, Developmental Therapeutics Program, Fairview Center, Ste 205, 1003 West Seventh St, Frederick, MD 21701, (e-mail: hollingm{at}mail.nih.gov)

The preclinical research and human clinical trials necessary for developing anticancer therapeutics are costly. One contributor to these costs is preclinical rodent efficacy studies, which, in addition to the costs associated with conducting them, often guide the selection of agents for clinical development. If inappropriate or inaccurate recommendations are made on the basis of these preclinical studies, then additional costs are incurred. In this commentary, I discuss the issues associated with preclinical rodent efficacy studies. These include the identification of proper preclinical efficacy models, the selection of appropriate experimental endpoints, and the correct statistical evaluation of the resulting data. I also describe important experimental design considerations, such as selecting the drug vehicle, optimizing the therapeutic treatment plan, properly powering the experiment by defining appropriate numbers of replicates in each treatment arm, and proper randomization. Improved preclinical selection criteria can aid in reducing unnecessary human studies, thus reducing the overall costs of anticancer drug development.

Manuscript received March 5, 2008; revised August 1, 2008; accepted September 3, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

In This Issue
J Natl Cancer Inst 2008 100: 1485. [Extract] [Full Text] [PDF]

Improved Rodent Trials Can Speed Cancer Drug Development
J Natl Cancer Inst 2008 100: 1486. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
I. Poggesi, G. de Nicolao, M. Germani, and M. Rocchetti
Re: Antitumor Efficacy Testing in Rodents
J Natl Cancer Inst, November 18, 2009; 101(22): 1592 - 1593.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.